Benzodiazepines, methadone and buprenorphine: Interactions and clinical management

American Journal on Addictions

Volumn 19, Issue 1, 2010, Pages 59-72

  Lintzeris, Nicholas ^a,c   Nielsen, Suzanne ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c RPAH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; BUPRENORPHINE; CARBAMAZEPINE; DIAZEPAM; DOSULEPIN; METHADONE; MIDAZOLAM; OPIATE; TEMAZEPAM;

ADJUVANT THERAPY; ANXIETY DISORDER; CLINICAL STUDY; CLINICAL TRIAL; DRUG DEPENDENCE; DRUG INTERACTION; DRUG USE; HEALTH HAZARD; HUMAN; MORTALITY; NONHUMAN; OPIATE ADDICTION; REVIEW; SLEEP DISORDER; WITHDRAWAL SYNDROME;

BENZODIAZEPINES; BUPRENORPHINE; CLINICAL PROTOCOLS; DRUG INTERACTIONS; HUMANS; METHADONE; OPIOID-RELATED DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 77149142289     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2009.00007.x     Document Type: Review

References (123)

1. Barnas C, Rossmann M, Roessler H, et al. Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: Familiarity and preference. J Clin Psychopharmacol. 1992 12 : 397 402.
2. Gelkopf M, Bleich A, Hayward R, et al. Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: A 1 year prospective study in an Israeli clinic. Drug Alcohol Depend. 1999 55 : 63 68. (Pubitemid 29222004)
3. Iguchi MY, Handelsman L, Bickel WK, et al. Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend. 1993 32 : 257 266.
4. Stitzer ML, Griffiths RR, McLellan AT, et al. Diazepam use among methadone maintenance patients: Patterns and dosages. Drug Alcohol Depend. 1981 8 : 189 199.
5. Hartog J, Tusel DJ. Valium use and abuse by methadone maintenance clients. Int J Addict. 1987 22 : 1147 1154.
6. San L, Torrens M, Castillo C, et al. Consumption of buprenorphine and other drugs among heroin addicts under ambulatory treatment: Results from cross sectional studies in 1988-1990. Addiction. 1993 88 : 1341 1349.
7. Nielsen S, Dietze P, Lee N, et al. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction. 2007 102 : 616 622.
8. Thirion X, Lapierre V, Micallef J, et al. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend. 2002 65 : 197 204.
9. Lavie E, Fatseas M, Denis C, et al. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: Correlates of use, abuse and dependence. Drug Alcohol Depend. 2009 99 : 338 344.
10. Darke S, Hall W, Ross M, et al. Benzodiazepine use and HIV risk-taking behaviour among injecting drug users. Drug Alcohol Depend. 1992 31 : 31 36.
11. Darke S, Hall W. Levels and correlates of polydrug use among heroin users and regular amphetamine users. Drug Alcohol Depend. 1995 39 : 231 235.
12. Williams H, Oyefeso A, Ghodse AH. Benzodiazepine misuse and dependence among opiate addicts in treatment. Irish J Psychol Med. 1996 13 : 62 64.
13. Miller N, Gold M. Abuse, addiction, tolerance and dependence to benzodiazepines in medical and nonmedical populations. Am J Drug Alcohol Abuse. 1991 17 : 27 37.
14. Perera K, Tulley M, Jenner F. The use of benzodiazepines among drug addicts. Br J Addict. 1987 82 : 511 516.
15. Ross J, Darke S. The nature of benzodiazepine dependence among heroin users in Sydney, Australia. Addiction. 2000 95 : 1785 1793.
16. Brands B, Blake J, Marsh DC, et al. The impact of benzodiazepine use on methadone maintenance treatment outcomes. J Addict Dis. 2008 27 : 37 48.
17. Darke SG, Ross JE, Hall WD. Benzodiazepine use among injecting heroin users. Med J Australia. 1995 162 : 645 647.
18. Forsyth AJ, Farquhar D, Gemmell M, et al. The dual use of opioids and temazepam by drug injectors in Glasgow (Scotland). Drug Alcohol Depend. 1993 32 : 277 280.
19. Breen CL, Degenhardt LJ, Bruno RB, et al. The effects of restricting publicly subsidised temazepam capsules on benzodiazepine use among injecting drug users in Australia. Med J Australia. 2004 181 : 300 304.
20. Bond A, Seijas D, Dawling S, et al. Systematic absorption and abuse liability of snorted flunitrazepam. Addiction. 1994 89 : 821 830.
21. Marsden J, Gossop M, Stewart D, et al. Psychiatric symptoms among clients seeking treatment for drug dependence. Intake data from the National Treatment Outcome Research Study. Br J Psychiatry. 2000 176 : 285 289. (Pubitemid 30179850)
22. Ross J, Teesson M, Darke S, et al. The characteristics of heroin users entering treatment: Findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005 24 : 411 418. (Pubitemid 43024040)
23. Olajide D, Lader M. Depression following withdrawal from long-term benzodiazepine use: A report of four cases. Psychol Med. 1984 14 : 937 940.
24. Peles E, Schreiber S, Adelson M. Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients. Drug Alcohol Depend. 2006 82 : 103 110.
25. Wang D, Teichtahl H, Drummer O, et al. Central sleep apnea in stable methadone maintenance treatment patients. Chest. 2005 128 : 1348 1356.
26. Fry CL, Bruno RB. Recent trends in benzodiazepine use by injecting drug users in Victoria and Tasmania. Drug Alcohol Rev. 2002 21 : 363 367.
27. Nielsen S, Bruno R, Carruthers S, et al. Investigation of pharmaceutical misuse amongst drug treatment clients. Report commissioned by the Ministerial Council on Drug Strategy through the Cost Shared Funding Model with the Victorian Department of Human Services. Melbourne : Turning Point Alcohol and Drug Centre Inc 2008.
28. Spiga R, Huang DB, Meisch RA, et al. Human methadone self-administration: Effects of diazepam pretreatment. Exp Clin Psychopharmacol. 2001 9 : 40 46.
29. Fountain J, Griffiths P, Farrell M, et al. Benzodiazepines in polydrug-using repertoires: The impact of the decreased availability of temazepam gel-filled capsules. Drugs Edu Prevent Pol. 1999 6 : 61 69.
30. Backmund M, Meyer K, Henkel C, et al. Co-consumption of benzodiazepines in heroin users, methadone-substituted and codeine-substituted patients. J Addict Dis. 2005 24 : 17 29.
31. Bleich A, Gelkopf M, Weizman T, et al. Benzodiazepine abuse in a methadone maintenance treatment clinic in Israel: Characteristics and a pharmacotherapeutic approach. Isr J Psychiatry Relat Sci. 2002 39 : 104 112.
32. Maxwell JC, Pullum TW, Tannert K. Deaths of clients in methadone treatment in Texas: 1994-2002. Drug Alcohol Depend. 2005 78 : 73 81.
33. Morgan O, Griffiths C, Hickman M. Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993-2004. Int J Epidemiol. 2006 35 : 1579 1585.
34. Williamson PA, Foreman KJ, White JM, et al. Methadone-related overdose deaths in South Australia, 1984-1994. How safe is methadone prescribing Med J Australia. 1997 166 : 302 305.
35. Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction. 2000 95 : 77 84. (Pubitemid 30096754)
36. Kintz P. Deaths involving buprenorphine: A compendium of French cases. Forensic Sci Int. 2001 121 : 65 69.
37. Kintz P. A new series of 13 buprenorphine-related deaths. Clin Biochem. 2002 35 : 513 516.
38. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: A report on 20 fatalities. J Anal Toxicol. 1998 22 : 430 434.
39. Lai SH, Yao YJ, Lo DST. A survey of buprenorphine related deaths in Singapore. Forensic Sci Int. 2006 162 : 80 86.
40. Degenhardt L, Larance BK, Bell JR, et al. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Med J Aust. 2009 191 : 161 165.
41. Thirion X, Micallef J, Barrau K, et al. Observation of psychoactive substance consumption: Methods and results of the French OPPIDUM programme. Eur Addict Res. 2001 7 : 32 36.
42. Rooney S, Kelly G, Bamford L, et al. Co-abuse of opiates and benzodiazepines. Irish Med Sci. 1999 168 : 36 41.
43. Sellers, EM, Ciraulo DA, DuPont RL, et al. Alprazolam and benzodiazepine dependence. J Clin Psychiatry. 1993 54S : 64 75.
44. Wolf B, Griffiths RR. Physical dependence on benzodiazepines: Differences within the class. Drug Alcohol Depend. 1991 29 : 153 156.
45. Farre M, Teran M, Roset P, et al. Abuse liability of flunitrazepam among methadone-maintained patients. Psychopharmacology. 1998 140 : 486 495.
46. Arendt RM, Greenblatt DJ, DeJong RH, et al. In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. J Pharmacol Exp Ther. 1983 227 : 98 106.
47. Stafford J, Degenhardt L, Blacke E, et al. Australian Drug Trends 2005: Findings from the Illicit Drug Reporting System (IDRS). In : NDARC Monograph No. 59. Sydney, Australia 2006 : p. 139.
48. Griffiths RR, Wolf B. Relative abuse liability of different benzodiazepines in drug abusers. J Clin Psychopharmacol. 1990 40 : 237 243.
49. Mintzer MZ, Griffiths RR. An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers. Behav Pharmacol. 2005 16 : 579 584.
50. Schminder J, Greenblatt DJ, von Moltke LL, et al. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: Implications for diazepam disposition in humans. J Clin Psychopharmacol. 1996 16 : 267 272.
51. Chang Y, Moody DE. Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes. Eur J Clin Pharmacol. 2005 60 : 875 881.
52. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004 16 : 36 44.
53. Wu D, Otton SV, Sproule BA, et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol. 1993 35 : 30 34. (Pubitemid 23016955)
54. Spaulding TC, Minium L, Kotake AN, et al. The effect of diazepam on the metabolism of methadone by the liver of methadone dependent rats. Drug Metab Dispos. 1974 2 : 458 463.
55. Shah NS, Patel VO, Donald AG. Effect of diazepam, desmethylimipramine, and SKF 525-A on the disposition of levo-methadone in mice after single or double injection. Drug Metab Dispos. 1979 7 : 241 242.
56. Liu S, Evans DB, Wang RIH. Correlation of urinary excretion of methadone metabolites with methadone metabolism and analgesia in the rat. J Pharmacol Exp Ther. 1978 204 : 67.
57. Iribarne C, Dreano Y, Bardou LG, et al. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology. 1997 117 : 13 23. (Pubitemid 27063996)
58. Pond SM, Tong TG, Benowitz NL, et al. Lack of effect of diazepam on methadone metabolism in methadone-maintained addicts. Clin Pharmacol Ther. 1982 31 : 139 143.
59. Preston KL, Griffiths RR, Cone EJ, et al. Diazepam and methadone blood levels following concurrent administration of diazepam and methadone. Drug Alcohol Depend. 1986 18 : 195 202.
60. Kobayashi K, Yamamoto T, Chiba K, et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos. 1998 26 : 818 821.
61. Ohtani M, Kotaki H, Nishitateno K, et al. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther. 1997 281 : 428 433.
62. Megarbane B, Marie N, Pirnay S, et al. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol. 2006 212 : 256 267.
63. Ibrahim RB, Wilson JG, Thorsby ME, et al. Effect of Buprenorphine on CYP3A Activity in Rat and Human Liver Microsomes. Life Sci. 2000 66 : 1293 1298.
64. Zhang W, Ramamoorthy Y, Tyndale RF, et al. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes P450 in vitro. Drug Metab Dispo. 2003 31 : 768 772.
65. Megarbane B, Pirnay S, Borron SW, et al. Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. Toxicol Lett. 2005 157 : 211 219.
66. Kilicarslan T, Sellers EM. Lack of interaction of buprenorphine with flunitrazepam metabolism. Am J Psychiatry. 2000 157 : 1164 1166.
67. Pirnay S, Megarbane B, Decleves X, et al. Buprenorphine alters desmethylflunitrazepam disposition and flunitrazepam toxicity in rats. Toxicol Sci. 2008 106 : 64 73.
68. Gueye P, Borron S, Risede P, et al. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol Sci. 2002 65 : 107 114.
69. Nielsen S, Taylor DA. The effect of buprenorphine and benzodiazepines on respiration in the rat. Drug Alcohol Depend. 2005 79 : 95 101.
70. Pirnay SO, Megarbane B, Borron SW, et al. Effects of various combinations of benzodiazepines with buprenorphine on arterial blood gases in rats. Basic Clin Pharmacol Toxicol. 2008 103 : 228 239.
71. Lintzeris N, Mitchell TB, Bond A, et al. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J Clin Psychopharmacol. 2006 26 : 274 283.
72. Nielsen S, Lintzeris N, Lee N, Bond A, et al. Examining the interaction between alprazolam and buprenorphine/naloxone in opioid substitution treatment patients. Paper presented at: The College on Problems of Drug Dependence Annual Meeting. Quebec, Canada 2008.
73. McCormick GY, White WJ, Zagon IS, et al. Effects of diazepam on arterial blood gas concentrations and pH of adult rats acutely and chronically exposed to methadone. J Pharmacol Exp Ther. 1984 230 : 353 359.
74. Borron S, Monier C, Risede P, et al. Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat. Hum Exp Toxicol. 2002 21 : 599 605.
75. Preston KL, Griffiths RR, Stitzer ML, et al. Diazepam and methadone interactions in methadone maintenance. Clin Pharmacol Ther. 1984 36 : 534 541.
76. Lintzeris N, Mitchell TB, Bond AJ, et al. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug Alcohol Depend. 2007 91 : 187 194.
77. Nielsen S, Lintzeris N, Lee N, et al. Pharmacodynamic interactions of alprazolam in methadone and buprenorphinenaloxone patients. Paper presented at: The College on Problems of Drug Dependence (CPDD) 70th Annual Meeting. San Juan, PR 2008.
78. Darke S, Sims J, McDonald S, et al. Cognitive impairment among methadone maintenance patients. Addiction. 2000 95 : 687 695.
79. Mintzer MZ, Correia CJ, Strain EC. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Drug Alcohol Depend. 2004 74 : 205 209.
80. Barker MJ, Greenwood KM, Jackson M, et al. Cognitive effects of long-term benzodiazepine use: A meta-analysis. CNS Drugs. 2004 18 : 37 48.
81. Curran HV. Benzodiazepines, memory and cognitive function. In : Trimble MR, Hindmarch IP, eds. Benzodiazepines. Philadelphia, PA : Biomedical Publishing 2000 : 17 27.
82. Rapeli P, Fabritius C, Kalska H, et al. Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: Longitudinal change in comparison to healthy individuals. Subst Abuse Treat Prev Policy. 2009 4 : 6.
83. Nutt DJ, Malizia AL. New insights into the role of the GABAA-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001 179 : 390 396.
84. Duka T, Cumin R, Haefely W, et al. Naloxone blocks the effect of diazepam and meprobamate on conflict behaviour in rats. Pharmacol Biochem Behav. 1981 15 : 115 117.
85. Soubrie P, Jobert A, Thiebot MH. Differential effects on naloxone against the diazepam-induced release of behavior in rats in three aversive situations. Psychopharmacol. 1980 69 : 101 105.
86. Cox RF, Collins MA. The effects of benzodiazepines on human opioid receptor binding and function. Anesth Analg. 2001 93 : 354 358.
87. Dan'ura T, Kurokawa T, Yamashita A, et al. Inhibition of rat brain adenylate cyclase activity by benzodiazepine through the effects on Gi and catalytic proteins. Life Sci. 1988 42 : 469 475.
88. Megarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression? : Possible mechanisms and therapeutic consequences. Toxicol Rev. 2006 25 : 79 85.
89. Kalyuzhny AE, Dooyema J, Wessendorf MW. Opioid-and GABA(a) receptors are co-expressed by neurons in rat brain. Neuroreport. 2000 11 : 2625 2628.
90. Weil JV, McCullough RE, Kline JS, et al. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. N Engl J Med. 1975 292 : 1103 1106.
91. Berkenbosch A, Teppema LJ, Olievier CN, et al. Influences of morphine on the ventilatory response to isocapnic hypoxia. Anesthesiology. 1997 86 : 1342 1349.
92. Teichtahl H, Wang D, Cunnington D, et al. Ventilatory responses to hypoxia and hypercapnia in stable methadone maintenance treatment patients. Chest. 2005 128 : 1339 1347.
93. Gross JB, Blouin RT, Zandsberg S, et al. Effect of flumazenil on ventilatory drive during sedation with midazolam and alfentanil. Anesthesiology. 1996 85 : 713 720.
94. Bailey PL, Pace NL, Ashburn MA, et al. Frequent hypoxemia and apnea after sedation with midazolam and fentanyl. Anesthesiology. 1990 73 : 826 830.
95. Gerak LR, Brandt MR, France CP. Studies on benzodiazepines and opioids administered alone and in combination in rhesus monkeys - ventilation and drug discrimination. Psychopharmacol. 1998 137 : 164 174.
96. Kellogg S, Melia D, Khuri E, et al. Adolescent and young adult heroin patients: Drug use and success in methadone maintenance treatment. J Addict Dis. 2006 25 : 15 25.
97. Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend. 2006 82 : 103 110.
98. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004 CD002207.
99. Hartikainen S, Lonnroos E, Louhivuori K. Medication as a risk factor for falls: Critical systematic review. J Gerontol A Biol Sci Med Sci. 2007 62 : 1172 1181.
100. Substance Abuse & Mental Health Services Administration. SAMHSA DASIS Report: Older adults in substance abuse treatment. Rockville, MD : Office of Applied Studies, SAMHSA 2005 : 1 3.
101. Fitzgerald RL, Rexin DA, Herold DA. Detecting benzodiazepines: Immunoassays compared with negative chemical ionization gas chromatography/mass spectrometry. Clin Chem. 1994 40 : 373 380.
102. Charney DS, Mihic SJ, Harris RA. Hypnotics and Sedatives. In : Laurence L, Brunton P, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, Medical Publishing Division 2006.
103. Kupfer DJ, Reynolds CF. Management of Insomnia. N Engl J Med. 1997 336 : 341 346.
104. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000 162 : 225 233.
105. Glovinsky PB, Yang CM, Dubrovsky B, et al. Nonpharmacologic strategies in the management of insomnia: Rationale and implementation. Sleep Med Clin. 2008 3 : 189 204.
106. Hoffman EJ, Mathew SJ. Anxiety disorders: A comprehensive review of pharmacotherapies. Mt Sinai J Med. 2008 75 : 248 262.
107. Katzman MA. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs. 2009 23 : 103 120.
108. Stitzer M, Petry N. Contingency management for treatment of substance abuse. Annu Rev Clin Psychol. 2006 2 : 411 434.
109. Chutuape MA, Silverman K, Stitzer M. Contingent reinforcement sustains post-detoxification abstinence from multiple drugs: A preliminary study with methadone patients. Drug Alcohol Depend. 1999 54 : 69 81.
110. Stitzer ML, Bigelow GE, Liebson IA, et al. Contingent reinforcement for benzodiazepine-free urines: Evaluation of a drug abuse treatment intervention. J Appl Behav Anal. 1982 15 : 493 503.
111. Denis C, Auriacombe M, Fatsas M, et al. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev. 2006 3 : CD005194.
112. Schweizer E, Rickels K, Case WG, et al. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy: Effects on withdrawal severity and outcome. Arch Gen Psychiatry. 1991 48 : 448 452.
113. Parr JM, Kavanagh DJ, Cahill L, et al. Effectiveness of current treatment approaches for benzodiazepine discontinuation: A meta-analysis. Addiction. 2009 104 : 13 24.
114. Nakao M, Takeuchi T, Nomura K, et al. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic. Psychiatry Clin Neurosci. 2006 60 : 605 610.
115. Zitman FG, Couvee JE. Chronic benzodiazepine use in general practice patients with depression: An evaluation of controlled treatment and taper-off: Report on behalf of the Dutch Chronic Benzodiazepine Working Group. Br J Psychiatry. 2001 178 : 317 324.
116. Rickels K, Schweizer E, Garcia Espana F, et al. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: Effects on withdrawal symptoms and taper outcome. Psychopharmacol. 1999 141 : 1 5.
117. Oude Voshaar RC, Couvee JE, Van Balkom AJ, et al. Strategies for discontinuing long-term benzodiazepine use: Meta-analysis. Br J Psychiatry. 2006 189 : 213 220.
118. Weizman T, Gelkopf M, Melamed Y, et al. Treatment of benzodiazepine dependence in methadone maintenance treatment patients: A comparison of two therapeutic modalities and the role of psychiatric comorbidity. Aust N Z J Psychiatry. 2003 37 : 458 463.
119. McDuff DR, Schwartz RP, Tommasello A, et al. Outpatient benzodiazepine detoxification procedure for methadone patients. J Subst Abuse Treat. 1993 10 : 297 302.
120. Elliott L, Glenday J, Freeman L, et al. Reducing diazepam prescribing for illicit drug users: A randomised control study. Drug Alcohol Rev. 2005 24 : 25 31.
121. Wickes WA, Darke S, Ross J. Clobazam maintenance among methadone maintenance patients with problematic benzodiazepine use: Five case studies. Drug Alcohol Rev. 2000 19 : 401 405.
122. Peles E, Hetzroni T, Bar-Hamburger R, et al. Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: A double-blind randomized clinical trial. Addiction. 2007 102 : 1947 1953.
123. NSW Department of Health. NSW Drug and Alcohol Withdrawal Clinical Practice Guidelines. NSW Department of Health. 2008.